Assessment of resynchronization therapy on functional status and quality of life in patients requiring an implantable defibrillator

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue 12, 2009, Pages 1509-1519

  Pinter, Arnold ^a   Mangat, Iqwal ^a   Korley, Victoria ^a   Connolly, Stuart ^b   Connors, Sean ^c   Gardner, Martin ^d   Philippon, Francois ^e   Sterns, Larry ^f   Thibault, Bernard ^g   Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f Vancouver Cardiac Arrhythmia Trials   (Canada)

^g MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Cardiac resynchronization therapy; Congestive heart failure; Echocardiography; Quality of life; Radionuclide angiocardiography

Indexed keywords

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE VOLUME; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCINTIANGIOGRAPHY; WALKING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GATED BLOOD-POOL IMAGING; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 70449713367     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02543.x     Document Type: Article

References (23)

1. The antiarrhythmics versus implantable defibrillators (AVID) investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997 337 : 1576 1583.
2. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000 101 : 1297 1302.
3. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000 102 : 748 754.
4. Gregoratos G, Abrams J, Epstein AE, Friedman RA, Hayes DL, Hlatky MA, Kerber RE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol 2002 40 : 1703 1719.
5. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002 346 : 1845 1853.
6. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 352 : 1539 1549. (Pubitemid 40517094)
7. McAlister FA, Ezekowitz JA, Wiebe N, Rowe B, Spooner C, Crumley E, Hartling L, et al. Systematic review: Cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004 141 : 381 390.
8. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 350 : 2140 2150.
9. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003 289 : 2685 2694.
10. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, Lieberman R, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004 110 : 2864 2868.
11. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003 42 : 1454 1459.
12. Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M, Roy D. Quality of life improves with treatment in the Canadian trial of atrial fibrillation. Am Heart J 2002 143 : 984 990.
13. Kuhlkamp V, for the InSync 7272 ICD Worldwide Investigators. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J Am Coll Cardiol 2002 39 : 790 797.
14. Van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, Atkinson P, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996 77 : 843 850.
15. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Eur Heart J 2000 21 : 1387 1396.
16. Tang AS, Ellenbogen KA. A futuristic perspective on clinical studies of cardiac resynchronization therapy for heart failure patients. Curr Opin Cardiol 2006 21 : 78 82.
17. Moss AJ, Brown MW, Cannom DS. Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): Design and clinical protocol. Ann Noninvasive Electrocardiol 2005 10 : 34 43.
18. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City cardiomyopathy questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 2000 35 : 1245 1255.
19. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996 94 : 2800 2806.
20. Havranek EP, Simon TA, L'Italien G, Smitten A, Hauber AB, Chen R, Lapuerta P. The relationship between health perception and utility in heart failure patients in a clinical trial: Results from an OVERTURE substudy. J Card Fail 2004 10 : 339 343.
21. Carter C, Holiday DB, Grothues C, Nwasuruba C, Stocks J, Tiep B. Criterion validity of the Duke Activity Status Index for assessing functional capacity in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2002 22 : 298 308.
22. Rostagno C, Olivo G, Comeglio M, Boddi V, Banchelli M, Galanti G, Gensini GF. Prognostic value of 6-minute walk corridor test in patients with mild-to-moderate heart failure: Comparison with other methods of functional evaluation. Eur J Heart Fail 2003 5 : 247 252.
23. Luther SA, McCullough PA, Havranek EP, Rumsfeld JS, Jones PG, Heidenreich PA, Peterson ED, et al. The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail 2005 11 : 414 421.